Bola-amphiphilic dendrimers with tunable architecture for ROS-responsive precision delivery of doxorubicin.

Authors

Dandan Zhu, Shuting Lin, Lingmin Ji, Lei Liu, Manman Wang, Yuanzheng Huang, Shengxiang Liang, Xin Li, Jiaxuan Chen, Yun Li, Chunyong Wu, Shengmei Wu, Ildikó Bácskay, Ferenc Fenyvesi, Xiaoxuan Liu

Published in

International journal of pharmaceutics. Pages 127556. Oct 17, 2026. Epub Oct 17, 2026.

Abstract

Stimuli-responsive nanocarriers capable of precise intracellular drug release are critical for improving the efficacy and safety of cancer chemotherapy. However, many existing systems suffer from limited structural tunability and incomplete integration of molecular architecture, self-assembly, and responsiveness, which constrains tumor delivery and therapeutic performance. Here, we report reactive oxygen species (ROS)-responsive bola-amphiphilic dendrimers with tunable dendron generations, bola4A and bola8A, as a platform for doxorubicin (DOX) delivery and systematic comparison. Both dendrimers displayed high drug-loading capacities and stable nanoassembly formation, whereas bola4A, with lower-generation PAMAM dendrons, permitted more efficient stimulus penetration into the nanosystems. This architectural feature enhanced ROS- and pH-triggered drug release, promoted cellular uptake, and accelerated endosomal escape. Importantly, modulation of dendron generation systematically altered nanoparticle architecture and responsiveness, directly dictating therapeutic efficacy. Consequently, bola4A/DOX nanoparticles achieved superior tumor accumulation and tissue penetration, together with improved anticancer efficacy in vitro and in ovarian cancer SKOV3 xenograft models and reduced systemic toxicity relative to free DOX. These results establish dendritic architecture as a key determinant of stimuli-responsiveness and drug delivery performance, and provide a rational framework for the design of next-generation stimuli-responsive nanomedicines tailored to pathological microenvironments.

PMID:
42892454
Bibliographic data and abstract were imported from PubMed on 18 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.